ChemoCentryx, Inc. (CCXI) EPS Estimated At $-0.25

October 13, 2018 - By Marguerite Chambers

ChemoCentryx, Inc. (NASDAQ:CCXI) LogoInvestors sentiment increased to 1.59 in 2018 Q2. Its up 0.59, from 1 in 2018Q1. It increased, as 11 investors sold ChemoCentryx, Inc. shares while 28 reduced holdings. 28 funds opened positions while 34 raised stakes. 26.37 million shares or 8.85% more from 24.22 million shares in 2018Q1 were reported.
Winch Advisory Svcs Ltd Limited Liability Company holds 400 shares. Macquarie Grp Limited has 9,900 shares. Aqr Capital Management accumulated 22,364 shares. Daiwa Secs Grp Inc Inc has 0% invested in ChemoCentryx, Inc. (NASDAQ:CCXI) for 269 shares. Amer Century accumulated 163,871 shares or 0% of the stock. Moreover, Fernwood Mngmt Limited Liability Com has 0.07% invested in ChemoCentryx, Inc. (NASDAQ:CCXI) for 10,000 shares. Bnp Paribas Arbitrage accumulated 0% or 738 shares. Adams Diversified Equity Fund has 43,000 shares. Gotham Asset Mgmt Ltd has 11,717 shares for 0% of their portfolio. Millennium Mgmt Lc reported 0.01% in ChemoCentryx, Inc. (NASDAQ:CCXI). Ameritas Invest Prns has 2,120 shares. Acadian Asset Mgmt Ltd Limited Liability Company has invested 0.04% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI). Switzerland-based Credit Suisse Ag has invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). 118,778 are held by Bankshares Of Ny Mellon. Jacobs Levy Equity Management invested in 0.01% or 43,708 shares.

Since May 1, 2018, it had 0 buys, and 12 insider sales for $7.89 million activity. $152,028 worth of stock was sold by Schall Thomas J. on Thursday, June 28. 100 shares were sold by KANAYA SUSAN M, worth $1,410.

Analysts expect ChemoCentryx, Inc. (NASDAQ:CCXI) to report $-0.25 EPS on November, 6.They anticipate $0.12 EPS change or 92.31 % from last quarter’s $-0.13 EPS. After having $-0.14 EPS previously, ChemoCentryx, Inc.’s analysts see 78.57 % EPS growth. The stock increased 2.20% or $0.22 during the last trading session, reaching $10.24. About 82,230 shares traded. ChemoCentryx, Inc. (NASDAQ:CCXI) has risen 51.30% since October 13, 2017 and is uptrending. It has outperformed by 35.68% the S&P500.

ChemoCentryx, Inc. (NASDAQ:CCXI) Ratings Coverage

Among 5 analysts covering ChemoCentryx (NASDAQ:CCXI), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. ChemoCentryx had 5 analyst reports since May 2, 2018 according to SRatingsIntel. The stock of ChemoCentryx, Inc. (NASDAQ:CCXI) earned “Neutral” rating by JP Morgan on Tuesday, August 14.

ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. The company has market cap of $515.88 million. The Company’s lead drug candidate is Avacopan , an orally-administered small molecule that is a selective inhibitor of the complement C5a receptor (C5Ar), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV). It has a 30.57 P/E ratio. The firm also engages in developing CCX140, an inhibitor of the chemokine receptor known as CCR2 for patients with focal segmental glomerulosclerosis (FSGS), a debilitating kidney disease; Vercirnon for the treatment of patients with moderate-to-severe Crohn's diseases; CCX872, a selective inhibitor of the human CCR2 that has completed Phase I clinical trial for the treatment of pancreatic cancer; CCX507, which has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and Th17 cells for the treatment of psoriasis, rheumatoid arthritis, asthma, and multiple sclerosis.

More notable recent ChemoCentryx, Inc. (NASDAQ:CCXI) news were published by: Globenewswire.com which released: “ChemoCentryx Announces Proposed Public Offering of Common Stock” on September 26, 2018, also Nasdaq.com with their article: “Mid-Morning Market Update: Markets Open Higher; Conagra Misses Q1 Views” published on September 27, 2018, Nasdaq.com published: “ChemoCentryx to Present at the Cantor Fitzgerald 2018 Global Healthcare Conference” on September 26, 2018. More interesting news about ChemoCentryx, Inc. (NASDAQ:CCXI) were released by: Nasdaq.com and their article: “Mid-Day Market Update: Crude Oil Up 1.5%; Altimmune Shares Plunge” published on September 28, 2018 as well as Seekingalpha.com‘s news article titled: “ChemoCentryx launches $75M stock offering” with publication date: September 26, 2018.

ChemoCentryx, Inc. (NASDAQ:CCXI) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

>